Views of Medicare-for-All Hold Steady As the Trump Administration and Congress weigh policy options to address high prescription drug prices, a fourth of people taking prescription drugs (24%) and seniors taking drugs (23%) say it is difficult for them…
With increased national attention towards prescription drug costs, this poll examines the public’s experiences with prescription medicine and their views on current policy proposals brought forth by congressional lawmakers and the Trump administration,…
Margot Sanger-Katz of The New York Times, Paige Winfield Cunningham of The Washington Post and Jennifer Haberkorn of the Los Angeles Times join KHN’s Julie Rovner to discuss the new “Medicare-for-all” bill introduced by House Democrats, the grilling of pharmaceutical company CEOs by a Senate committee and new Trump administration rules that take aim at Planned Parenthood. Plus, Rovner interviews KHN’s Julie Appleby about the latest “Bill of the Month” installment.
The Senate Finance Committee grilled executives from seven major drugmakers on Tuesday.
Tuesday’s Senate hearing with pharma CEOs will tackle the same issues as the famous Kefauver hearings in 1960.
Confrontational hearings 60 years ago sparked remarkably similar quotes about drug prices and health care policy.
In an emerging new tactic against the rising toll of opioid deaths, California, Ohio, Virginia and Arizona are among the states requiring physicians to offer patients naloxone when they give them prescriptions for the powerful painkillers. The Food and Drug Administration is weighing a national recommendation to do so.
Medicare and many private insurers view prescribing drugs to improve sexual function as a lifestyle issue that’s not medically necessary to pay for.
Antiviral medications, including those that treat hepatitis C and HIV/AIDS, cost the Medicaid program more money (before rebates) than any other group of outpatient prescription drugs for each year from 2014 to 2017, according to a new KFF analysis. Th…
Although the outpatient drug benefit accounts for only 6% of total Medicaid spending, drug spending has increased by double digits in recent years, and is expected to grow faster than most other Medicaid services in the next 10 years. This issue brief …
